That is wrong. Active M1 macrophages are what denote a hot tumor. Leronlimab switches the M2 macrophages to M1 causing the tumor to go from cold to hot. The rise in PD-L1 is just a response by the tumor to protect itself from the killer M1 macrophages.
Quote:and ccr5 inhibition isnt the only way to induce increased PD-L1 to prime a cold tumor for ICIs.
I wouldn't say it's CCR5 inhibition, rather it's Leronlimab's CCR5 inhibition because it's the only one that I've ran across that increases rather than decreases PD-L1. There may be ways to increase PD-L1 without increasing active M1 macrophages, but doing so would be rather pointless if the immune system isn't going to attack the tumor.